Computeruser.com
Latest News

Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule

FRANKLIN, Mass. Feb. 17, 2011

$1 billion $12 billion

Patrick T. Mooney

The Symphony tCGM System incorporates Echo’s proprietary Prelude SkinPrep System, with a noninvasive wireless biosensor and a wireless monitor or handheld device for needle-free, continuous monitoring of glucose levels.  

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

December 31, 2009

Connect With Us:

www.echotx.com

www.twitter.com/echotx

www.facebook.com/echotx

For More Information:

Patrick T. Mooney, M.D.

Media: Richard Stern

Chairman and Chief Executive Officer

Stern & Co.

(508)530-0329

(212) 888-0044

SOURCE Echo Therapeutics, Inc.

Leave a comment

seks shop - izolasyon
basic theory test book basic theory test